{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-281807","form_type":"8-K","ticker":"FBRX","cik":"0001419041","company_name":"Forte Biosciences, Inc.","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.362689+00:00","generated_at":"2026-05-16T19:49:33.711119+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Forte Biosciences Q3 net loss $17.7M; cash $93.4M; three FB102 readouts in 2026","bullets":["Net loss of $17.7M ($0.99 per share) for Q3 2025 vs $8.4M loss in Q3 2024.","R&D expenses $15.2M, up from $5.9M YoY, driven by FB102 clinical programs.","Cash and equivalents $93.4M as of Sept 30, 2025, up from $22.2M at year-end 2024.","FB102 phase 2 celiac disease enrolling US sites; topline data expected in 2026.","Phase 1b vitiligo data expected 1H26; alopecia areata study enrolling, data in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-281807","json":"https://secwatch.observer/filing/0001193125-25-281807.json","markdown":"https://secwatch.observer/filing/0001193125-25-281807.md","text":"https://secwatch.observer/filing/0001193125-25-281807.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419041/000119312525281807/0001193125-25-281807-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419041/000119312525281807/d77724d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:49:33.711119+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}